Takeda Pharmaceutical Company Limited
COMBINATION OF SPLEEN TYROSINE KINASE INHIBITORS AND OTHER THERAPEUTIC AGENTS

Abstract:

This disclosure provides combination therapies for treating cancers. In particular, this disclosure provides methods for treating non-Hodgkin lymphoma comprising administering a combination of a SYK inhibitor and a second therapeutic agent.